
Orphenadrine NEW
Price | $52 | $68 | $110 |
Package | 5mg | 10mg | 25mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2025-05-26 |
Product Details
Product Name: Orphenadrine | CAS No.: 83-98-7 |
Purity: 99.38% | Supply Ability: 10g |
Release date: 2025/05/26 |
Product Introduction
Bioactivity
Name | Orphenadrine |
Description | Orphenadrine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that inhibits clonal HERG channels in a concentration-dependent manner, producing an IC of 0.85 μM in HEK cells.Orphenadrine is an antagonist of central and peripheral muscarinic receptors. Attenuation is blocked by mutations in pore residues Y652 or F656. Orphenadrine has antispasmodic, analgesic, and anticholinergic activity and protects against glutamatergic neurotoxicity in vitro and in vivo.Orphenadrine has inhibitory effects on sodium channels and can be used in the treatment of Parkinson's disease. |
In vitro | Orphenadrine decreased CYP2B6 marker activity up to 45-57% in human liver microsomes and up to 80-97% in cell microsomes containing cDNA-expressed CYP2B6. Orphenadrine strongly decreased CYP2D6 marker activity by 80-90%. Orphenadrine also partially decreased the CYP1A2, CYP2A6, CYP3A4, and CYP2C19 marker activities.[4] |
In vivo | Orphenadrine (75 mg/kg/day; i.p.; for 3 days) was associated with a 2-fold induction of total hepatic P-450, a 5- and 2.4-fold induction of androstenedione 16 beta- and 6 beta-hydroxylase activity, respectively, and formation of an orphenadrine-P-450 MI complex. Western blots of orphenadrine-induced microsomes revealed a 20-fold increase in P-450 PB-B/D-immunoreactive protein.[2] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (185.61 mM), Sonication is recommended. |
Keywords | SodiumChannel | Sodium Channel | Orphenadrine | NMDA receptor | muscarinic receptor | Cholinergic |
Inhibitors Related | Adiphenine hydrochloride | Phenytoin sodium | Procaine | Urethane | Ribavirin | Lidocaine | Valproic Acid | L-Aspartic aicd sodium | Lidocaine hydrochloride | D-Menthol | Choline chloride | Propoxur |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bitter Compound library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$46.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-06-10 | |
$0.00/25kg |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-04-10 | |
$10.00/1Kg/Drum |
VIP5Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2021-07-16 |
- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY